Sir Gregory Paul Winter is a British molecular biologist best known for his work on the therapeutic use of monoclonal antibodies, who was awarded the 2018 Nobel Prize in Chemistry (shared) for his work on the phage display of antibodies. This work led to the development of the antibody Humira, used for treatment of immune inflammatory disorders such as rheumatoid arthritis, and for several years the world’s top selling pharmaceutical drug.
As well as a prolific inventor with more than 400 patents to his name, Gregory Winter is a successful entrepreneur having founded companies based on his antibody and peptide inventions. Most notably, in 1989 he founded Cambridge Antibody Technology (CAT), which was sold to AstraZeneca for $1.3B in 2006, and in 2009 founded Bicycle Therapeutics, which listed on Nasdaq in 2019. As entrepreneur and inventor, he has had first-hand experience in IP related challenges to drive commercial success. The technologies he developed have earned the Medical Research Council more than $1bn in royalties.
Gregory Winter was born in Leicester in Great Britain but was brought up until the age of 13 in West Africa, studied at the University of Cambridge and earned his PhD in 1977 at the MRC Laboratory of Molecular Biology in Cambridge. He continued to work there until 2012, when he was appointed by the Queen as Master of Trinity College Cambridge, stepping down in 2019.